Amneal Pharmaceuticals (AMRX) Asset Writedowns and Impairment (2017 - 2026)

Amneal Pharmaceuticals' Asset Writedowns and Impairment history runs 10 years deep, the most recent figure standing at $13.4 million for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment fell 43.58% year-over-year to $13.4 million; the TTM figure through Mar 2026 stood at $36.1 million (up 2069.09% YoY), while the FY2025 annual figure was $22.8 million, up 2376.52% from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $13.4 million, up from -$16000.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $41.8 million in Q2 2023, with the low at -$62.7 million in Q4 2024.
• The 5-year median for Asset Writedowns and Impairment is $14.2 million (2022), against an average of $10.1 million.
• The sharpest annual moves came in 2023 and 2024: Asset Writedowns and Impairment soared 315.2% in 2023, then plunged 708.95% in 2024.
• Amneal Pharmaceuticals' Asset Writedowns and Impairment stood at -$4.8 million in 2022, then jumped by 315.2% to $10.3 million in 2023, then tumbled by 708.95% to -$62.7 million in 2024, then jumped by 99.97% to -$16000.0 in 2025, then soared by 83556.25% to $13.4 million in 2026.
• Business Quant data shows AMRX's Asset Writedowns and Impairment at $13.4 million in Q1 2026, -$16000.0 in Q4 2025, and $22.8 million in Q3 2025.